<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383718</url>
  </required_header>
  <id_info>
    <org_study_id>1.0</org_study_id>
    <nct_id>NCT03383718</nct_id>
  </id_info>
  <brief_title>DSE vs. FFR in SCAD and BYSTANDER Lesions</brief_title>
  <acronym>DSE-vs-FFR</acronym>
  <official_title>Comparison of Dobutamine Stress Echocardiography and Fractional Flow Reserve in Patients With Moderate Coronary Artery Disease: Stable and Non-culprit Lesions Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bajcsy-Zsilinszky Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Semmelweis University Heart and Vascular Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bajcsy-Zsilinszky Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enrollment:

        -  Patients with stable coronary artery disease (SCAD) and moderate coronary artery
           stenoses (30-70 %)

        -  Patients with acute myocardial infarction and moderate stenosis of non-culprit arteries
           (NCL; BYSTANDER LESION)

      Aims:

        -  To assess the diagnostic accuracy of dobutamine stress echocardiography (DSE) and
           invasive fractional flow reserve (FFR) measurement

        -  To assess the prognostic impact of reclassification by a mismatching negative test

      Hypothesis:

        -  DSE and FFR have similar prognostic value in both clinical settings (SCAD and NCL)

        -  Considering the strong negative predictive value of both DSE and FFR, one negative test
           is sufficiently enough to defer revascularisation, even in the case of mismatch
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Easy accessibility made fractional flow reserve (FFR) a widely accepted method to evaluate
      myocardial ischaemia in patients with moderate coronary artery stenosis, although the
      prognostic value for &quot;hard&quot; endpoints such as myocardial infarction and cardiovascular death
      is equivocal.

      Dobutamine stress echocardiography (DSE) is a useful and safe non-invasive functional test
      for myocardial ichaemia evaluation. There are robust data confirming the prognostic value of
      DSE regarding the same &quot;hard&quot; endpoints.

      In patients with SCAD there are clear recommendations in the recent guidelines both for DSE
      guided or FFR guided revascularization but the data about prognosis is limited, especially in
      the case of FFR guidance. The outcome is also equivocal if there is a difference between the
      invasive and non-invasive test result.

      In patients with acute myocardial infarction, more than 50% of patients have multivessel
      disease. There are clear recommendations for the management of infarct related artery,
      however controversy still exists for the management of angiographically moderate NCLs.

      In DSE vs. FFR prospective trial, the Investigators plan to perform both the DSE and FFR
      tests in the above mentioned clinical settings, to investigate the correlation between them.
      The causes of differences between them would be investigated as well as the prognostic impact
      of reclassification by a second test (either DSE or FFR).

      If both tests are positive, revascularisation is planned to be performed (PCI Group). In
      cases of either double negative or mismatching tests, optimal medical therapy will be chosen
      (OMT Group) with clinical follow up of at least 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Myocardial Infarction</measure>
    <time_frame>From baseline to at least 2 years</time_frame>
    <description>Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least one value above the 99th percentile upper reference limit (URL) and with at least one of the following: Symptoms of ischaemia. New or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch block (LBBB).
Development of pathological Q waves in the ECG. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Identification of an intracoronary thrombus by angiography or autopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target Vessel Revascularisation</measure>
    <time_frame>From baseline to at least 2 years</time_frame>
    <description>The Investigated Vessel need Revascularisation because of at least Canadian Cardiology Society Angina Class III</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>From baseline to at least 2 years</time_frame>
    <description>Death occurs due to Cardiovascular cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angina</measure>
    <time_frame>From baseline to at least 2 years</time_frame>
    <description>Rehospitalisation due to Angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure</measure>
    <time_frame>From baseline to at least 2 years</time_frame>
    <description>Rehospitalisation due to Heart Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Cardiac Death</measure>
    <time_frame>From baseline to at least 2 years</time_frame>
    <description>Death occurs due to Non-Cardiovascular cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Target Vessel Revascularisation</measure>
    <time_frame>From baseline to at least 2 years</time_frame>
    <description>The Non-Investigated Vessel need Revascularisation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>DSE+/FFR+</arm_group_label>
    <description>Patients with positive Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve Revascularisation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSE+/FFR- or DSE-/FFR+ or DSE-/FFR-</arm_group_label>
    <description>Patients with positive Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve
Patients with negative Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve
Patients with negative Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve
Optimal Medical Treatment/OMT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Revascularisation</intervention_name>
    <description>Percutaneous coronary intervention or coronary artery bypass surgery</description>
    <arm_group_label>DSE+/FFR+</arm_group_label>
    <other_name>PCI or CABG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimal Medical Treatment/OMT</intervention_name>
    <description>Standard of care in stable coronary artery disease or after acute myocardial infarction.</description>
    <arm_group_label>DSE+/FFR- or DSE-/FFR+ or DSE-/FFR-</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In this study, the suitable patients have at least one moderate coronary artery stenosis
        identified by coronary angiography.

        There will be patients with stable coronary artery disease and patients with acute
        myocardial infarction having at least one non-culprit vessel stenoses.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18 years

          -  Moderate Coronary Stenosis (30-70 %)

          -  Stable coronary artery disease or patients with acute myocardial infarction and at
             least one moderate non-culprit vessel stenosis

        Exclusion Criteria:

          -  Left Main Coronary artery stenosis

          -  Age&gt;80 years

          -  Known non-cardiovascular disease with poor prognosis

          -  Patients for whom coronary angiography or stress echocardiography is contraindicated
             per institutional standard of care (e.g. History of severe and/or anaphylactic
             contrast reaction)

          -  Inability to provide informed consent;

          -  Inability to cooperate with the investigation

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Péter Andrássy, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bajcsy-Zsilinszky Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012 Sep 13;367(11):991-1001. doi: 10.1056/NEJMoa1205361. Epub 2012 Aug 27. Erratum in: N Engl J Med. 2012 Nov;367(18):1768. Mobius-Winckler, Sven [corrected to Möbius-Winkler, Sven].</citation>
    <PMID>22924638</PMID>
  </reference>
  <reference>
    <citation>Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009 Jan 15;360(3):213-24. doi: 10.1056/NEJMoa0807611.</citation>
    <PMID>19144937</PMID>
  </reference>
  <reference>
    <citation>Christou MA, Siontis GC, Katritsis DG, Ioannidis JP. Meta-analysis of fractional flow reserve versus quantitative coronary angiography and noninvasive imaging for evaluation of myocardial ischemia. Am J Cardiol. 2007 Feb 15;99(4):450-6. Epub 2006 Dec 20.</citation>
    <PMID>17293182</PMID>
  </reference>
  <reference>
    <citation>Gaibazzi N, Rigo F, Lorenzoni V, Molinaro S, Bartolomucci F, Reverberi C, Marwick TH. Comparative prediction of cardiac events by wall motion, wall motion plus coronary flow reserve, or myocardial perfusion analysis: a multicenter study of contrast stress echocardiography. JACC Cardiovasc Imaging. 2013 Jan;6(1):1-12. doi: 10.1016/j.jcmg.2012.08.009. Epub 2012 Dec 5.</citation>
    <PMID>23219414</PMID>
  </reference>
  <reference>
    <citation>Pattanshetty DJ, Bhat PK, Gandhi S, Pillai DP, Aneja A. Comparing stress testing and fractional flow reserve to evaluate presence, location and extent of ischemia in coronary artery disease. Indian Heart J. 2015 Jan-Feb;67(1):50-5. doi: 10.1016/j.ihj.2015.02.010. Epub 2015 Feb 25.</citation>
    <PMID>25820051</PMID>
  </reference>
  <reference>
    <citation>Cortigiani L, Rigo F, Gherardi S, Bovenzi F, Molinaro S, Picano E, Sicari R. Coronary flow reserve during dipyridamole stress echocardiography predicts mortality. JACC Cardiovasc Imaging. 2012 Nov;5(11):1079-85. doi: 10.1016/j.jcmg.2012.08.007.</citation>
    <PMID>23153906</PMID>
  </reference>
  <reference>
    <citation>Ojaghi-Haghighi Z, Abtahi F, Fazlolah S, Moladoust H, Maleki M, Gholami S. Coronary flow reserve, strain and strain rate imaging during pharmacological stress before and after percutaneous coronary intervention: comparison and correlation. Echocardiography. 2011 May;28(5):570-4. doi: 10.1111/j.1540-8175.2011.01366.x. Epub 2011 May 4.</citation>
    <PMID>21539600</PMID>
  </reference>
  <reference>
    <citation>Dagdelen S, Yuce M, Emiroglu Y, Ergelen M, Pala S, Tanalp AC, Izgi A, Kirma C. Correlation between the tissue Doppler, strain rate, strain imaging during the dobutamine infusion and coronary fractional flow reserve during catheterization: a comparative study. Int J Cardiol. 2005 Jun 22;102(1):127-36.</citation>
    <PMID>15939109</PMID>
  </reference>
  <reference>
    <citation>Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguadé-Bruix S, Pizzi MN, Todiere G, Gimelli A, Schroeder S, Drosch T, Poddighe R, Casolo G, Anagnostopoulos C, Pugliese F, Rouzet F, Le Guludec D, Cappelli F, Valente S, Gensini GF, Zawaideh C, Capitanio S, Sambuceti G, Marsico F, Perrone Filardi P, Fernández-Golfín C, Rincón LM, Graner FP, de Graaf MA, Fiechter M, Stehli J, Gaemperli O, Reyes E, Nkomo S, Mäki M, Lorenzoni V, Turchetti G, Carpeggiani C, Marinelli M, Puzzuoli S, Mangione M, Marcheschi P, Mariani F, Giannessi D, Nekolla S, Lombardi M, Sicari R, Scholte AJ, Zamorano JL, Kaufmann PA, Underwood SR, Knuuti J; EVINCI Study Investigators. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imaging. 2015 Mar;8(3). pii: e002179. doi: 10.1161/CIRCIMAGING.114.002179.</citation>
    <PMID>25711274</PMID>
  </reference>
  <reference>
    <citation>Takx RA, Blomberg BA, El Aidi H, Habets J, de Jong PA, Nagel E, Hoffmann U, Leiner T. Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis. Circ Cardiovasc Imaging. 2015 Jan;8(1). pii: e002666. doi: 10.1161/CIRCIMAGING.114.002666. Review.</citation>
    <PMID>25596143</PMID>
  </reference>
  <reference>
    <citation>van der Sijde JN, Boiten HJ, van Domburg RT, Schinkel AF. Long-Term (&gt;10 Years) Prognostic Value of Dobutamine Stress Echocardiography in a High-Risk Cohort. Am J Cardiol. 2016 Apr 1;117(7):1078-83. doi: 10.1016/j.amjcard.2016.01.002. Epub 2016 Jan 14.</citation>
    <PMID>26839054</PMID>
  </reference>
  <reference>
    <citation>Harb SC, Marwick TH. Prognostic value of stress imaging after revascularization: a systematic review of stress echocardiography and stress nuclear imaging. Am Heart J. 2014 Jan;167(1):77-85. doi: 10.1016/j.ahj.2013.07.035. Epub 2013 Nov 21. Review.</citation>
    <PMID>24332145</PMID>
  </reference>
  <reference>
    <citation>Cortigiani L, Bigi R, Sicari R, Landi P, Bovenzi F, Picano E. Prognostic value of pharmacological stress echocardiography in diabetic and nondiabetic patients with known or suspected coronary artery disease. J Am Coll Cardiol. 2006 Feb 7;47(3):605-10. Epub 2006 Jan 18.</citation>
    <PMID>16458144</PMID>
  </reference>
  <reference>
    <citation>Jung PH, Rieber J, Störk S, Hoyer C, Erhardt I, Nowotny A, Voelker W, Weidemann F, Ertl G, Klauss V, Angermann CE. Effect of contrast application on interpretability and diagnostic value of dobutamine stress echocardiography in patients with intermediate coronary lesions: comparison with myocardial fractional flow reserve. Eur Heart J. 2008 Oct;29(20):2536-43. doi: 10.1093/eurheartj/ehn204. Epub 2008 May 21.</citation>
    <PMID>18499651</PMID>
  </reference>
  <reference>
    <citation>Weidemann F, Jung P, Hoyer C, Broscheit J, Voelker W, Ertl G, Störk S, Angermann CE, Strotmann JM. Assessment of the contractile reserve in patients with intermediate coronary lesions: a strain rate imaging study validated by invasive myocardial fractional flow reserve. Eur Heart J. 2007 Jun;28(12):1425-32. Epub 2007 May 15.</citation>
    <PMID>17504804</PMID>
  </reference>
  <reference>
    <citation>Samady H, Lepper W, Powers ER, Wei K, Ragosta M, Bishop GG, Sarembock IJ, Gimple L, Watson DD, Beller GA, Barringhaus KG. Fractional flow reserve of infarct-related arteries identifies reversible defects on noninvasive myocardial perfusion imaging early after myocardial infarction. J Am Coll Cardiol. 2006 Jun 6;47(11):2187-93.</citation>
    <PMID>16750683</PMID>
  </reference>
  <reference>
    <citation>Lachance P, Déry JP, Rodés-Cabau J, Potvin JM, Barbeau G, Bertrand OF, Gleeton O, Larose E, Nguyen CM, Noël B, Proulx G, Roy L, De Larochellière R. Impact of fractional flow reserve measurement on the clinical management of patients with coronary artery disease evaluated with noninvasive stress tests prior to cardiac catheterization. Cardiovasc Revasc Med. 2008 Oct-Dec;9(4):229-34. doi: 10.1016/j.carrev.2008.02.002.</citation>
    <PMID>18928947</PMID>
  </reference>
  <reference>
    <citation>Steinberg EH, Madmon L, Patel CP, Sedlis SP, Kronzon I, Cohen JL. Long-term prognostic significance of dobutamine echocardiography in patients with suspected coronary artery disease: results of a 5-year follow-up study. J Am Coll Cardiol. 1997 Apr;29(5):969-73.</citation>
    <PMID>9120183</PMID>
  </reference>
  <reference>
    <citation>Danad I, Szymonifka J, Twisk JWR, Norgaard BL, Zarins CK, Knaapen P, Min JK. Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis. Eur Heart J. 2017 Apr 1;38(13):991-998. doi: 10.1093/eurheartj/ehw095. Review.</citation>
    <PMID>27141095</PMID>
  </reference>
  <reference>
    <citation>Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J Koolen JJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996 Jun 27;334(26):1703-8.</citation>
    <PMID>8637515</PMID>
  </reference>
  <reference>
    <citation>Pingitore A, Picano E, Varga A, Gigli G, Cortigiani L, Previtali M, Minardi G, Colosso MQ, Lowenstein J, Mathias W Jr, Landi P. Prognostic value of pharmacological stress echocardiography in patients with known or suspected coronary artery disease: a prospective, large-scale, multicenter, head-to-head comparison between dipyridamole and dobutamine test. Echo-Persantine International Cooperative (EPIC) and Echo-Dobutamine International Cooperative (EDIC) Study Groups. J Am Coll Cardiol. 1999 Nov 15;34(6):1769-77.</citation>
    <PMID>10577568</PMID>
  </reference>
  <reference>
    <citation>Thomas D, Xie F, Smith LM, O'Leary E, Smith K, Olson J, Nalty K, Hess R, Graham M, Therrien S, Porter TR. Prospective randomized comparison of conventional stress echocardiography and real-time perfusion stress echocardiography in detecting significant coronary artery disease. J Am Soc Echocardiogr. 2012 Nov;25(11):1207-14. doi: 10.1016/j.echo.2012.08.016. Epub 2012 Sep 19.</citation>
    <PMID>22998856</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bajcsy-Zsilinszky Hospital</investigator_affiliation>
    <investigator_full_name>Peter Andrassy MD.PhD.</investigator_full_name>
    <investigator_title>Clinical Lead of Cardiology Department</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Fractional Flow Reserve</keyword>
  <keyword>Dobutamine Stress Echocardiography</keyword>
  <keyword>Stable Coronary Artery Disease</keyword>
  <keyword>Bystander Coronary Artery Disease</keyword>
  <keyword>Non-Culprit Lesions</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Results will be shared ONLY with the patient's other physicians.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

